Trials / Completed
CompletedNCT05620160
Study of RAY1216 Tablets Compared With Placebo in Patients With Mild to Moderate COVID-19
A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study of RAY1216 Tablets in Patients With Mild to Moderate SARS-CoV-2 Infection
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,359 (actual)
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of RAY1216 tablets in the treatment of mild to moderate SARS-CoV-2 infection. The total study duration is up to 28 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RAY1216 | RAY1216（tablet） |
| DRUG | Placebo | placebo （tablet） |
Timeline
- Start date
- 2022-11-12
- Primary completion
- 2023-01-19
- Completion
- 2023-03-28
- First posted
- 2022-11-17
- Last updated
- 2023-05-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05620160. Inclusion in this directory is not an endorsement.